M. Stamouli, Christina Seitopoulou, Georgia Kalliora, Nikoletta Renesi, A. Mourtzikou
{"title":"Vaccination Rate for COVID-19 in a Primary Healthcare Center in Greece","authors":"M. Stamouli, Christina Seitopoulou, Georgia Kalliora, Nikoletta Renesi, A. Mourtzikou","doi":"10.24018/ejbiomed.2023.2.4.79","DOIUrl":null,"url":null,"abstract":"The novel coronavirus SARS-CoV-2 has been the contributing factor to the COVID-19 disease pandemic, since early 2020. It first appeared in December 2019 and since then rapidly spread worldwide. The severe symptoms of COVID-19 disease, especially in the population groups with higher risk of infection or disease complications, along with the increased mortality rates determined the need for adequate protection and prevention measures to be taken. From the beginning of the pandemic, efforts have been made to develop and produce vaccines that could stop the spread of the disease. The vaccination in most countries was performed in phases, with priority to population groups with a higher risk of infection or disease complications, such as the elderly and patients with chronic diseases, and to population groups with a high risk of professional exposure. This study presented data from the vaccination program, implemented at a primary healthcare center in Greece, that served as a vaccination center during the pandemic. Relying on the results, both the attendance rate and the vaccination rate were very high, which proves that the necessity of the vaccine is well established and that vaccination hesitancy is mitigated among the population served at the Nikea Health Center.","PeriodicalId":72970,"journal":{"name":"European journal of biomedical research","volume":"14 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of biomedical research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24018/ejbiomed.2023.2.4.79","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The novel coronavirus SARS-CoV-2 has been the contributing factor to the COVID-19 disease pandemic, since early 2020. It first appeared in December 2019 and since then rapidly spread worldwide. The severe symptoms of COVID-19 disease, especially in the population groups with higher risk of infection or disease complications, along with the increased mortality rates determined the need for adequate protection and prevention measures to be taken. From the beginning of the pandemic, efforts have been made to develop and produce vaccines that could stop the spread of the disease. The vaccination in most countries was performed in phases, with priority to population groups with a higher risk of infection or disease complications, such as the elderly and patients with chronic diseases, and to population groups with a high risk of professional exposure. This study presented data from the vaccination program, implemented at a primary healthcare center in Greece, that served as a vaccination center during the pandemic. Relying on the results, both the attendance rate and the vaccination rate were very high, which proves that the necessity of the vaccine is well established and that vaccination hesitancy is mitigated among the population served at the Nikea Health Center.